March 3 (Reuters) - The U.S. Food and Drug Administration has warned Novo Nordisk over a consumer ad for its blockbuster ...

FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.

Less than a month after the US Food and Drug Administration said a TV advertisement for Novo Nordisk A/S’ Wegovy weight-loss ...

It's rare to make it through an episode of your favorite show without seeing a commercial for a prescription drug that ...

Amid rapidly evolving media consumption habits and a federal push to limit direct-to-consumer drug advertising, pharma companies in 2026 and beyond are on track to continue their migration away from ...

Food and Drug Administration ‌has told Novo Nordisk ‌to stop running a consumer ad ​for its blockbuster diabetes drug Ozempic, saying the commercial makes false and misleading claims ‌about what ⁠the ...

The ethics of direct-to-consumer ads from pharmaceutical companies is being debated as the FDA looks towards possibly banning them altogether.

Direct-to-consumer drug advertising has long been opposed by the American Medical Association — and now the Trump ...

In Focus delivers deeper coverage of the political, cultural, and ideological issues shaping America. Published daily by senior writers and experts, these in-depth pieces go beyond the headlines to ...

Reliable, up-to-date figures are hard to come by, but according to a widely cited estimate, the U.S. pharmaceutical industry now spends more than US$6 billion on direct-to-consumer advertising, ...